20th MEET THE PROFESSOR

Advanced International Breast Cancer Course (AIBCC)

PADOVA, OCTOBER 24th-25th, 2024

www.accmed.org
Aims

Breast cancer research has been the frontrunner in many fields of cancer research: epidemiology, life-style and genetic risk factors, secondary prevention, conservative surgery, molecular classification, curative adjuvant therapies, neoadjuvant treatments, targeted agents, survival prolongation in advanced stages. Thanks to this knowledge, today many breast cancers can be prevented, most can be diagnosed at early stages and cured and the minority of patients at advanced stages can still enjoy a significant survival with a reasonable quality of life.

As a consequence of these major improvements, the bar of research and clinical excellence for breast cancer has raised even more.

New prognostic and predictive biomarkers are available, need to be validated and to be implemented in trial design and clinical practice. Risk-adapted surgery and radiation therapy allow for less and less invasive procedures. Multiple effective adjuvant therapies in the different molecular breast cancer subtypes, require a more precise definition of risk and predictivity of drug efficacy, to allow for a rational de-escalation or escalation of curative treatments. The impressive advances in the treatment of advanced breast cancers, envisage the possibility of cure with a multimodality approach for some patients and guarantee a prolonged survival for most of them with a rational sequencing of treatments.

The 20th AIBCC in Padova, will allow to sum up the most recent biological and clinical achievements and to allow an open and friendly discussion of clinical cases among key opinion leaders and participants.

Addressed to

Gynaecologists and obstetrics, medical oncologists, pathologists, radiologists, radiation oncologists, surgeons. Biologists, pharmacists, and nurses.

Educational material

The event educational material can be downloaded starting November 10th on askit.accmed.org
Programme

Thursday, October 24th

10.30 **Introduction to the Conference**
Pierfranco Conte, Valentina Guarneri, Philip Poortmans, Aleix Prat

**SESSION I – EVOLVING KNOWLEDGE OF BREAST CANCER BIOLOGY: IMPLICATIONS FOR STAGING, PROGNOSIS AND PREDICTION**
Chairpersons: Maria Vittoria Dieci, Hesham Ahmed Gaballah Elghazaly

11.00 **Gene expression tools in early-stage HR+/HER2- breast cancer: questioning the grey areas**
Alberto Zambelli

11.20 **The immune system and breast cancer: TNBC and beyond**
Marleen Kok

11.40 **DNA NGS-based biomarkers to inform treatment sequence in advanced breast cancer**
Mafalda Oliveira

12.00 **Tackling the biological diversity in HER2-positive breast cancer: clinical implications**
Aleix Prat

12.20 **Discussion**

12.50 **Lunch**

**SESSION II – LOCOREGIONAL Tx AND GENOMICS**
Chairpersons: Jacek Jassem, Eleftherios Mamounas

14.00 **Surgery of the axilla: is less always more?**
Oreste Gentilini

14.20 **Navigating RT option according to genetic risk profiles**
Philip Poortmans

14.40 **Evolving concepts in genetic testing: finding the balance**
Angela Toss

15.00 **Discussion**
SESSION III – EARLY BREAST CANCER: NEOADJUVANT AND POST-NEOADJUVANT THERAPY
Chairpersons: Pierfranco Conte, Sibylle Loibl

15.30 Modulation of neoadjuvant and post-neoadjuvant treatment in HER2+ (pert, TDM1, neratinib, trials)
Sibylle Loibl

15.50 Modulation of neoadjuvant and post-neoadjuvant treatment in TNBC (IO, PARPi, capecitabine)
Pierfranco Conte

16.10 Indication to and modalities of neoadjuvant Tx in HR+HER2 - BC
Valentina Guarneri

16.30 Discussion

17.00 Adjourn

17.15 Ceremony for the presentation of the University of Padua Award for Advances in Breast Cancer 2024

17.30 Lecture of the Awardee

18.00 Adjourn

The cocktail will take place in Caffè Pedrocchi, Via VIII Febbraio 15, Padua.

Friday, October 25th

SESSION IV – EARLY BREAST CANCER
Chairpersons: Valentina Guarneri, Aleix Prat

9.00 Enhancing efficacy of hormonal therapy in early breast cancer (bisphosphonates, extended, CDK4/6i, SERDs, PARPi…)
Stephen Johnston

9.20 Optimizing systemic treatment for small tumors depending on local treatments
Hope Rugo

9.40 The challenge of lobular breast cancer
Maria Vittoria Dieci
10.00  Discussion

10.30  Coffee break

11.00  Clinical Multidisciplinary Shooting Session 1
       Early Breast Cancer
Panelists:  Bettina Borisch, Hesham Ahmed Gaballah Elghazaly,
          Oreste Gentilini, Jacek Jassem, Sibylle Loibl, Eleftherios Mamounas,
          Alberto Marchet, Fedro A. Peccatori, Philip Poortmans, Aleix Prat

12.30  Lunch

SESSION V – METASTATIC BREAST CANCER: CONSOLIDATED
AND NEW ALGORITHMS
Chairpersons:  Pierfranco Conte, Sandra Swain

13.30  HR+ disease
       Current algorithm:  Claudio Vernieri
       Adapting the algorithm in a contemporary scenario:  Carmen Criscitiello

14.00  HER2+ disease
       Current algorithm:  Federica Miglietta
       Treatment sequences in new emerging populations:  Sandra Swain

14.30  Triple negative disease
       Current algorithm:  Gaia Griguolo
       Treatment sequences in new emerging populations:  Hope Rugo

15.00  Discussion

15.20  Clinical Multidisciplinary Shooting Session 2
       Advanced Breast Cancer
Panelists:  Pierfranco Conte, Hesham Ahmed Gaballah Elghazaly,
          Oreste Gentilini, Stephen Johnston, Philip Poortmans, Hope Rugo,
          Sandra Swain

16.40  Take home messages and adjourn
       Pierfranco Conte, Valentina Guarneri, Aleix Prat, Philip Poortmans
Honorary President

Gabriel N. Hortobagyi
Department of Breast Medical Oncology
The University of Texas - MD Anderson Cancer Center
Houston (USA)

Scientific Committee

Bettina Borisch
Institute of Global Health
University of Geneva (CH)

Maria Vittoria Dieci
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padova (I)

Hesham Ahmed Gaballah Elghazaly
Department of Clinical Oncology and nuclear medicine
University of A’inshams
Cairo (EG)

Jacek Jassem
Department of Oncology and Radiotherapy
Medical University of Gdansk (PL)

Stephen Johnston
NIHR Biomedical Research Centre for Cancer
Royal Marsden NHS Foundation Trust & Institute of Cancer Research
London (UK)

Sibylle Loibl
German Breast Group
University of Frankfurt (D)

Eleftherios Mamounas
Orlando Health Cancer Institute
Orlando (F)

Fedro Alessandro Peccatori
Department of Medical Oncology
European Institute of Oncology (IEO)
Milano (I)

Sandra Swain M.
Professor of Medicine,
Associate Dean Research Development
Georgetown University Medical Center
Washington (USA)

Directors

Pierfranco Conte
Coordinator Molecular Tumor Board, Rete Oncologica Veneta, Padova (I)
Scientific Director S. Camillo Hospital, IRCCS, Venezia (I)

Valentina Guarneri
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padova (I)

Philip Poortmans
Former president of ESTRO and of ECCO
Department of Radiation Oncology
Iridium Netwerk
University of Antwerp
Wilrijk-Antwerp (B)

Aleix Prat
Medical Oncology Department
Hospital Clinic
Barcelona (ES)
Speakers & Chairpersons

Carmen Criscitiello
Development Division of New Drugs for Innovative Therapies
Istituto Europeo di Oncologia (IEO)
Milano (I)

Oreste Davide Gentilini
Breast Unit
IRCCS S. Raffaele Hospital
Milano (I)

Gaia Griguolo
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padova (I)

Marleen Kok
Breast cancer immunotherapy
Netherlands Cancer Institute
Amsterdam (NL)

Alberto Marchet
Breast Surgery Unit 1
Istituto Oncologico Veneto IRCCS
University of Padova (I)

Federica Miglietta
Division of Medical Oncology 2
Istituto Oncologico Veneto IRCCS
Department of Surgery, Oncology and Gastroenterology
University of Padova (I)

Mafalda Oliveira
Medical Department of the Vall d’Hebron University
Hospital and Vall d’Hebron Institute of Oncology (VHIO)
Barcellona (E)

Hope Rugo
Breast Oncology Clinical Trials Program
UCSF Carol Franc Buck Breast Care Center
San Francisco (USA)

Angela Toss
Oncology Unit
AOU
Modena (I)

Claudio Vernieri
Institute of Molecular Oncology Oncology and Hemato-Oncology Department
IRCCS Istituto Nazionale dei Tumori
Milano (I)

Alberto Zambelli
Oncology Unit
IRCCS Humanitas
Rozzano – Milano (I)
UNIVERSITY OF PADOVA AWARD FOR ADVANCES IN BREAST CANCER 2024
The Scientific Committee will select young researchers (< 40 years from any
country) who have published in an international peer-reviewed journal, as the
principal author, a manuscript reporting important clinical or biological advances
in breast cancer. The Scientific Committee will select the final winner which will
be invited to present his/her study during the annual Conference.

FELLOWSHIPS
Some fellowship (for under 40) will be awarded including registration, 1 hotel
night and reimbursement of travel expenses (max of travel reimbursement
200,00).

UNDER 40
Accademia will provide a limited amount of free registrations for Physicians,
Biologists, Pharmacists and Nurses “Under 40”.

Official Language
The official language of the Meeting is English. No simultaneous translation will
be provided.
**CME**

Based on the in force regulations approved by the CNFC, Accademia Nazionale di Medicina (provider n. 31) will assign to the activity CME (31-419161): **7,7 CME points**.

Training objective: professional and technical content (knowledge and skills) specific to each profession, specialisation and highly specialised activity. Rare disease.

To obtain CME credits, participants must meet the following requirements:
1. Their declared profession/specialization must correspond to those accredited for CME.
2. They must attend at least 90% of the course.
3. They must complete the online meeting evaluation form.
4. They must pass the learning assessment test with at least 75% correct answers.
   Only one attempt is allowed.

The learning assessment test and meeting evaluation form must be submitted within three days of the event.

**Registration**

Online registration at [https://fad.accmed.org/course/info.php?id=1576](https://fad.accmed.org/course/info.php?id=1576) before **October 19th**; the application will be completed only after the payment of the registration fee:

- **€ 120,00**
- **€ 80,00** for graduate students
- **€ 80,00** for AIOM members

**CANCELLATION AND REFOUNDS**

- In order to cancel please give advise with a written communication to Accademia Nazionale di Medicina within 10 days from the beginning. A 70% of the registration fee will be returned. Any cancellation after that deadline will not be reimbursed.
Meeting Venue

Auditorium
Centro Culturale San Gaetano Altinate
Via Altinate, 71
Padova

How to reach the venue:

The Center is located in the ZTL area. We recommend the parking in Piazza Insurrezione in the historic center of Padova (the area is accessible and there are no electronic gates).
With the patronage of

INSTITUTIONS

PATROCINIO
REGIONE DEL VENETO

Comune di Padova

Università degli Studi di Padova

Azienda Ospedale Università Padova

Istituto Oncologico Veneto IRCCS

DiSCOOG
SCIENTIFIC SOCIETIES

AiOM
ASSOCIAZIONE ITALIANA ONCOLOGIA MEDICA

CIPOMO
Collegio Italiano dei Primari Oncologi Medici Ospedalieri

COMI
COLLEGIO ONCOLOGI MEDICI UNIVERSITARI

ESSO
The European Society of Surgical Oncology
Endorsed

ESTRO
Endorsed by

fondazione Periplo
Organizer

ACCADEMIA NAZIONALE DI MEDICINA
General Manager: Stefania Ledda
Via Martin Piaggio, 17/6
16122 Genova

Information and registration:
http://meettheprofessor.accmed.org
Ph. +39 051.6360080
info.bologna@accmed.org

Logistics and Technological Services

Forum Service
Via Martin Piaggio, 17/7
16122 Genova